Influence of Genetic variation of the β2 -Adrenergic receptor on lung diffusion in patients with cystic fibrosis

• Published in: Pulmonary pharmacology & therapeutics 2011-10, Vol.24 (5), p.610-616
• Main Authors: Traylor, Brittany R, Wheatley, Courtney M, Skrentny, Thomas T, Foxx-Lupo, William T, Phan, Hanna, Patanwala, Asad E, Morgan, Wayne J, Daines, Cori L, Sprissler, Ryan, Snyder, Eric M
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists - pharmacology; Adult; Albuterol - pharmacology; Carbon Monoxide - metabolism; Case-Control Studies; Cystic Fibrosis - genetics; Cystic Fibrosis - physiopathology; Diffusion; Female; Genetic Variation; Genotype; Humans; Lung - metabolism; Lung - physiopathology; Male; Medical Education; Oxygen - metabolism; Pulmonary/Respiratory; Receptors, Adrenergic, beta-2 - drug effects; Receptors, Adrenergic, beta-2 - genetics; Young Adult
• ISSN: 1094-5539; 1522-9629
• DOI: 10.1016/j.pupt.2011.06.001

Abstract Rationale Cystic fibrosis (CF) is a disease that adversely affects the lung resulting in a reduction in lung diffusion. Stimulation of the β2 -adrenergic receptors mediates mucociliary clearance and bronchodilation. We sought to determine the influence of an inhaled β-agonist on the diffusing capacity of the lungs for carbon monoxide (DLCO), alveolar-capillary membrane conductance ( DM ), pulmonary capillary blood volume ( V c), and peripheral oxygen saturation (SaO2 ) in subjects with CF, when compared to matched healthy subjects, according to genetic variation of the β2 -adrenergic receptor (ADRB2). Methods To determine this we recruited 18 subjects with CF and 20 healthy subjects (age = 23 ± 7 vs. 24±4years; ht = 168 ± 8 vs. 174 ± 12 cm; wt = 64 ± 16 vs. 70 ± 13 kg; BMI = 23 ± 4 vs. 23±3 kg/m2 ; FEV1  = 72 ± 27 vs. 92 ± 12%pred; VO2peak  = 45 ± 25 vs. 99 ± 24%pred, p